Post Profile






Phase 2 CAR-T study reports significant remission rates at 15-month follow up

(University of Texas M. D. Anderson Cancer Center) A study involving the recently approved CD19-targeting chimeric antigen receptor (CAR) T cell therapy shows that 42 percent of patients with aggressive large B-cell lymphoma remained in remission at 15 months following treatment with axi-cel (marketed as Yescarta?).
read more

share

Related Posts


Dana-Farber and Brigham and Women's researchers laud FDA approval of CAR T-cell therapy for non-Hodgkin Lymphoma

Health : Newswise Medical News

Following a successful clinical trial involving Dana-Farber Cancer Institute and Brigham and Women's Hospital, the first chimeric antigen receptor (CAR) T-cell therapy for adult cancers was approved by the Food and Drug Administrati...

Gilead's new drug keeps 56 percent of lymphoma trial patients alive

Health : Reuters: Health

(Reuters) - More than half of trial patients with an advanced, aggressive form of blood cancer lived for at least a year after one-time treatment with Yescarta, a novel therapy sold by Gilead Sciences Inc, according to study results...

Moffitt Cancer Center Study Shows Promising Clinical Activity, Safety Results of KTE-C19 in Aggressive B-Cell Non-Hodgkin Lymphoma

Health : Newswise Medical News

TAMPA, Fla. - Immune cellular therapy is a promising new area of cancer treatment. Anti-cancer therapeutics, such as chimeric antigen receptor (CAR) modified T cells, can be engineered to target tumor-associated antigens to attack a...

Roche lymphoma drug drives high remission rate, longer survival: study

Health : Reuters: Health

(Reuters) - An experimental Roche Holding AG drug, added to standard therapy, led to a far higher rate of remission and helped patients with an advanced, aggressive blood cancer live significantly longer than the standard treatment ...

Global CAR T therapy trial shows high rates of durable remission for NHL

Health : EurekAlert: Health

(University of Pennsylvania School of Medicine) In a pair of clinical trials stretching from Philadelphia to Tokyo, the chimeric antigen receptor (CAR) T cell therapy Kymriah? (formerly known as CTL019) demonstrated long-lasting rem...

Comments


Copyright © 2016 Regator, LLC